• 1
    Budman D. Vinorelbine (Navelbine): a third-generation Vinca alkaloid. Cancer Invest 1997; 15: 47590.
  • 2
    Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003; 63: 602631.
  • 3
    Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 2003; 89(Suppl 3): S915.
  • 4
    Goncalves A, Braguer D, Kamath K et al. Resistance to taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001; 98: 1173742.
  • 5
    Kavallaris M, Tait AS, Walsh BJ et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61: 58039.
  • 6
    Dumontet C, Isaac S, Souquet P et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005; 92: E2530.
  • 7
    Ferlini C, Raspaglio G, Mozzetti S et al. The seco-taxane IDN5390 is able to target class III b-tubulin and to overcome paclitaxel resistance. Cancer Res 2005; 65: 2397405.
  • 8
    Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005; 5: 6571.
  • 9
    Carlson RO. New tubulin targeting agents currently in clinical development. Expert Opin Investig Drugs 2008; 17: 70722.
  • 10
    Simoni D, Romagnoli R, Baruchello R et al. Novel combretastatin analogues endowed with antitumor activity. J Med Chem 2006; 49: 314352.
  • 11
    Tron G, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani A. Medicinal chemistry of combretastatin A4: present and future directions. J Med Chem 2006; 49: 303344.
  • 12
    Gourdeau H, Leblond L, Hamelin B et al. Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents. Mol Cancer Ther 2004; 3: 137584.
  • 13
    Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 118.
  • 14
    Hung H. Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts. Mol Cancer Ther 2007; 6: 214957.
  • 15
    Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 233542.
  • 16
    Dal Lago L, D’Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008; 13: 84558.
  • 17
    Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007; 64: S47.
  • 18
    Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs 2003; 7: 59.
  • 19
    Ho PY, Yeh TK, Yao HT et al. Enhanced oral bioavailability of paclitaxel by D-a-tocopheryl polyethylene glycol 400 succinate in mice. Int J Pharm 2008; 359: 17481.
  • 20
    Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther 2006; 6: 97382.
  • 21
    Bacher G, Nickel B, Emig P et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 2001; 61: 3929.
  • 22
    Li WT, Hwang DR, Chen CP et al. Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. J Med Chem 2003; 46: 170615.
  • 23
    Park S-Y, Lam W, Cheng Y-C. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 2002; 62: 45965.
  • 24
    Kuo CC, Hsieh HP, Pan WY et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004; 64: 46218.
  • 25
    Li WT, Hwang DR, Song JS et al. Synthesis and biological activities of 2-amino-1-arylidenamino imidazoles as orally active anticancer agents. J Med Chem 2010; 53: 240917.
  • 26
    Singer WD, Hersh RT, Himes RH. Effect of solution variables on the binding of vinblastine to tubulin. Biochem Pharmacol 1988; 37: 26916.
  • 27
    Kato Y, Salumbides BC, Wang XF et al. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 2007; 6: 7081.
  • 28
    Yeh TK, Li CM, Chen CP et al. Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91. Pharmacol Res 2010; 61: 10815.
  • 29
    Huang YC, Chen CT, Chen SC et al. A natural compound (ginsenoside Re) isolated from Panax ginseng as a novel angiogenic agent for tissue regeneration. Pharm Res 2005; 22: 63646.
  • 30
    Myers T, Chengedza S, Lightfoot S et al. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs 2009; 27: 30418.
  • 31
    Wang H-S, Hwang L-L, Sue H-F, Lee K-M, Chen C-T. A simple quantitative method for evaluation of angiogenesis activity. Assay Drug Dev Technol 2004; 2: 318.
  • 32
    Kwak HJ, Park MJ, Park CM et al. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 2006; 118: 271120.
  • 33
    Lee SH, Yoo SD, Lee KH. Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999; 724: 35763.
  • 34
    Chang YW, Chen WC, Lin KT et al. Development and validation of a liquid chromatography-tandem mass spectrometry for the determination of BPR0L075, a novel antimicrotuble agent, in rat plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 846: 1628.
  • 35
    Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 109314.
  • 36
    Ranade VV. Drug delivery systems 5A. Oral drug delivery. J Clin Pharmacol 1991; 31: 216.
  • 37
    van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci 2000; 11: 20714.
  • 38
    Brown D, Goosen TC, Chetty M, Hamman JH. Effect of oral contraceptives on the transport of chlorpromazine across the CACO-2 intestinal epithelial cell line. Eur J Pharm Biopharm 2003; 56: 15965.
  • 39
    Dahl SG, Strandjord RE. Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 1977; 21: 43748.
  • 40
    Mabuchi S, Terai Y, Morishige K et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 2008; 14: 77819.
  • 41
    Xu L, Zuch CL, Lin YS, Modi NB, Lum BL. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. Cancer Chemother Pharmacol 2008; 61: 60714.
  • 42
    Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 254455.